Provexis plans to ramp up Fruitflow earnings

BIOTECH firm Provexis is planning to spend the next year maximising the commercial potential of its main product Fruitflow.

The tomato-based drink which thins the blood and helps circulation is already being used in fruit juices, flavoured drinks and yoghurt drinks.

At the general meeting today chairman Dawson Buck will say: “Overall, our strategy for the coming year is to maximise the opportunity for Fruitflow, while continuing to build significant shareholder value in our technology pipeline.”

The AIM-listed firm, which has its research and development facility in Liverpool, has already sealed a long-term alliance deal with partner DSM Nutritional Products to commercialise Fruitflow in major global markets.

For the latest Provexis share price and company information click here

Today Mr Buck will spell out his vision for the product which has been put through initial manufacturing trials by DSM and will be on show at major trade exhibitions later in the year. DSM has also entered into commercial discussions with major brand owners.

The company is also keen to push on with more trials of a product for people with Crohn’s disease, an inflammatory disease of the gastrointestinal tract causing a wide variety of symptoms.

It also intends to carry out two further clinical trials in early 2011, one with the Institute of Food Research for reduction of cardiovascular inflammation, the second with the University of Liverpool for treatment of the hospital superbug c.difficile.

Mr Buck will add: “The management team are actively seeking new technologies to acquire and continue to screen a range of possible opportunities.”